Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients

Relapse is a major limitation of chimeric antigen receptor (CAR) T-cell therapy. Here, we speculated that decitabine (DAC) in combination with fludarabine and cyclophosphamide (FC) as a lymphodepletion regimen may improve the efficacy of CD19/CD22 CAR T-cell therapy. Fourteen of 26 patients with rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yunju, Dai, Haiping, Cui, Qingya, Liu, Sining, Kang, Liqing, Lian, Xiaying, Cui, Wei, Yin, Jia, Liu, Lingling, Cai, Mengjie, Yu, Lei, Wu, Depei, Tang, Xiaowen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084593/
https://www.ncbi.nlm.nih.gov/pubmed/37038230
http://dx.doi.org/10.1186/s40164-023-00397-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084593/
https://www.ncbi.nlm.nih.gov/pubmed/37038230
http://dx.doi.org/10.1186/s40164-023-00397-z

Ejemplares similares